Table 2.
Characteristics of ClinicalTrials.gov registered glutamine metabolic interventions for cancer therapy
| Therapeutic agents | Cancer type | NCT member | Phase | Combination therapy | Status |
|---|---|---|---|---|---|
| CB-839 | Leukemia | NCT02071927 | I | None | Completed |
| CB-839 | Hematological tumors | NCT02071888 | I | None | Completed |
| CB-839 | Solid tumors | NCT02071862 | I | None | Completed |
| CB-839 | Solid tumors and fluoropyrimidine resistant PIK3CA mutant colorectal cancer | NCT02861300 | I; II | None | Not yet recruiting |
| CB-839 | Advanced stage non-small cell lung cancer | NCT04250545 | I | Sapanisertib | Suspended (Drug supply issues) |
| CB-839 | Solid tumors | NCT03875313 | I; II | None | Completed (Slow enrollment) |
| CB-839 | Recurrent or refractory Multiple Myeloma | NCT03798678 | I | Carfilzomib | Active |
| CB-839 | Metastatic and refractory RAS wildtype colorectal cancer | NCT03263429 | I; II | Panitumumab; Irinotecan | Active |
| CB-839 | Platinum resistant BRCA -wild-type ovarian cancer | NCT03944902 | I | Niraparib | Terminated (Participant off study) |
| CB-839 | Solid tumors | NCT03965845 | I; II | Palbociclib | Completed |
| CB-839 | EGFR-mutated stage IV non-small cell lung cancer | NCT03831932 | I; II | Osimertinib | Recruiting |
| CB-839 | Advanced triple negative breast cancer | NCT03057600 | II | Paclitaxel | Completed |
| CB-839 | IDH-mutated diffuse astrocytoma or anaplastic astrocytoma | NCT03528642 | I | Radiation Therapy | Active |
| CB-839 | Renal cell carcinoma | NCT03163667 | II | Everolimus | Completed |
| CB-839 | Prostate cancer | NCT04824937 | II | Talazoparib | Unknown |
| CB-839 | Metastatic renal cell carcinoma | NCT03428217 | II | Cabozantinib | Completed |
| CB-839 | Melanoma; Clear cell renal cell carcinoma; Non-small cell lung cancer | NCT02771626 | I; II | Nivolumab | Terminated (Lack of efficacy) |
| CB-839 | Advanced solid tumor | NCT03872427 | II | No | Active |
| CB-839 | Advanced cervical cancer | NCT05521997 | II | Chemoradiation | Not yet recruiting |
| CB-839 | KEAP1 or NRF2-mutated, non-squamous NSCLC | NCT04265534 | II | Pembrolizumab | Terminated (Lack of efficacy) |
| IPN60090 | Advanced solid tumors | NCT03894540 | II | Pemobrolizumab | Terminated |
| IPN60090 | Advanced solid tumors | NCT05039801 | I | Bevacizumab; Paclitaxel | Recruiting |
| DRP-104 | Advanced solid tumors | NCT04471415 | I; II | Atezolizumab | Terminated |
| DRP-104 | Fibrolamellar hepatocellular carcinoma | NCT06027086 | I; II | Durvalumab | Not yet recruiting |